vs
ImmunityBio, Inc.（IBRX）与KKR Real Estate Finance Trust Inc.（KREF）财务数据对比。点击上方公司名可切换其他公司
ImmunityBio, Inc.的季度营收约是KKR Real Estate Finance Trust Inc.的1.5倍（$38.3M vs $25.8M），KKR Real Estate Finance Trust Inc.净利率更高（-101.7% vs -161.8%，领先60.1%），ImmunityBio, Inc.同比增速更快（407.0% vs -26.6%）
ImmunityBio, Inc.是一家处于临床阶段的生物技术企业，专注开发针对多种癌症及传染性疾病的下一代免疫疗法与候选疫苗，核心研发方向涵盖细胞疗法、抗体药物及靶向疫苗平台，主要运营市场位于美国。
KKR房地产金融信托公司是全球投资机构KKR旗下的专业房地产金融平台，主要发起、收购并管理优先担保商业地产贷款组合，抵押物多为美国各地的优质机构级商业地产，通过贷款利息收入为投资者提供稳定的经风险调整后的回报。
IBRX vs KREF — 直观对比
营收规模更大
IBRX
是对方的1.5倍
$25.8M
营收增速更快
IBRX
高出433.5%
-26.6%
净利率更高
KREF
高出60.1%
-161.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $38.3M | $25.8M |
| 净利润 | $-61.9M | $-26.2M |
| 毛利率 | 99.0% | — |
| 营业利润率 | -169.0% | -105.1% |
| 净利率 | -161.8% | -101.7% |
| 营收同比 | 407.0% | -26.6% |
| 净利润同比 | -4.7% | -229.6% |
| 每股收益（稀释后） | $-0.06 | $-0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IBRXKREF
| Q4 25 | $38.3M | $25.8M | ||
| Q3 25 | $32.1M | $25.3M | ||
| Q2 25 | $26.4M | $30.2M | ||
| Q1 25 | $16.5M | $31.3M | ||
| Q4 24 | $7.6M | $35.1M | ||
| Q3 24 | $6.1M | $37.0M | ||
| Q2 24 | — | $40.4M | ||
| Q1 24 | — | $39.1M |
净利润IBRXKREF
| Q4 25 | $-61.9M | $-26.2M | ||
| Q3 25 | $-67.3M | $13.8M | ||
| Q2 25 | $-92.6M | $-29.7M | ||
| Q1 25 | $-129.6M | $-4.9M | ||
| Q4 24 | $-59.2M | $20.3M | ||
| Q3 24 | $-85.7M | $-7.4M | ||
| Q2 24 | — | $25.8M | ||
| Q1 24 | — | $-3.1M |
毛利率IBRXKREF
| Q4 25 | 99.0% | — | ||
| Q3 25 | 99.4% | — | ||
| Q2 25 | 99.5% | — | ||
| Q1 25 | 99.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率IBRXKREF
| Q4 25 | -169.0% | -105.1% | ||
| Q3 25 | -173.5% | 50.4% | ||
| Q2 25 | -269.8% | -101.3% | ||
| Q1 25 | -390.1% | -18.3% | ||
| Q4 24 | -919.0% | 55.8% | ||
| Q3 24 | -1314.3% | -19.6% | ||
| Q2 24 | — | 63.3% | ||
| Q1 24 | — | -8.7% |
净利率IBRXKREF
| Q4 25 | -161.8% | -101.7% | ||
| Q3 25 | -209.8% | 54.4% | ||
| Q2 25 | -350.3% | -98.5% | ||
| Q1 25 | -784.9% | -15.5% | ||
| Q4 24 | -783.4% | 57.7% | ||
| Q3 24 | -1404.0% | -20.0% | ||
| Q2 24 | — | 63.9% | ||
| Q1 24 | — | -7.9% |
每股收益（稀释后）IBRXKREF
| Q4 25 | $-0.06 | $-0.49 | ||
| Q3 25 | $-0.07 | $0.12 | ||
| Q2 25 | $-0.10 | $-0.53 | ||
| Q1 25 | $-0.15 | $-0.15 | ||
| Q4 24 | $-0.08 | $0.22 | ||
| Q3 24 | $-0.14 | $-0.19 | ||
| Q2 24 | — | $0.29 | ||
| Q1 24 | — | $-0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $242.8M | $84.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-500.5M | $1.2B |
| 总资产 | $501.9M | $6.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资IBRXKREF
| Q4 25 | $242.8M | $84.6M | ||
| Q3 25 | $257.8M | $204.1M | ||
| Q2 25 | $153.7M | $107.7M | ||
| Q1 25 | $61.6M | $106.4M | ||
| Q4 24 | $149.8M | $104.9M | ||
| Q3 24 | $130.4M | $108.8M | ||
| Q2 24 | — | $107.2M | ||
| Q1 24 | — | $106.5M |
股东权益IBRXKREF
| Q4 25 | $-500.5M | $1.2B | ||
| Q3 25 | $-524.3M | $1.2B | ||
| Q2 25 | $-570.7M | $1.2B | ||
| Q1 25 | $-591.4M | $1.3B | ||
| Q4 24 | $-489.1M | $1.3B | ||
| Q3 24 | $-745.1M | $1.4B | ||
| Q2 24 | — | $1.4B | ||
| Q1 24 | — | $1.4B |
总资产IBRXKREF
| Q4 25 | $501.9M | $6.5B | ||
| Q3 25 | $519.0M | $6.5B | ||
| Q2 25 | $402.1M | $6.8B | ||
| Q1 25 | $303.8M | $6.6B | ||
| Q4 24 | $382.9M | $6.4B | ||
| Q3 24 | $364.6M | $6.8B | ||
| Q2 24 | — | $7.1B | ||
| Q1 24 | — | $7.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-70.4M | $72.3M |
| 自由现金流经营现金流 - 资本支出 | $-71.3M | — |
| 自由现金流率自由现金流/营收 | -186.2% | — |
| 资本支出强度资本支出/营收 | 2.4% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-308.8M | — |
8季度趋势，按日历期对齐
经营现金流IBRXKREF
| Q4 25 | $-70.4M | $72.3M | ||
| Q3 25 | $-68.9M | $18.5M | ||
| Q2 25 | $-79.7M | $21.1M | ||
| Q1 25 | $-85.9M | $15.9M | ||
| Q4 24 | $-85.1M | $132.6M | ||
| Q3 24 | $-98.8M | $49.1M | ||
| Q2 24 | — | $30.6M | ||
| Q1 24 | — | $34.5M |
自由现金流IBRXKREF
| Q4 25 | $-71.3M | — | ||
| Q3 25 | $-69.6M | — | ||
| Q2 25 | $-80.8M | — | ||
| Q1 25 | $-87.0M | — | ||
| Q4 24 | $-87.3M | — | ||
| Q3 24 | $-101.6M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率IBRXKREF
| Q4 25 | -186.2% | — | ||
| Q3 25 | -217.2% | — | ||
| Q2 25 | -305.9% | — | ||
| Q1 25 | -526.9% | — | ||
| Q4 24 | -1155.4% | — | ||
| Q3 24 | -1663.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度IBRXKREF
| Q4 25 | 2.4% | — | ||
| Q3 25 | 2.3% | — | ||
| Q2 25 | 4.1% | — | ||
| Q1 25 | 6.8% | — | ||
| Q4 24 | 28.0% | — | ||
| Q3 24 | 45.7% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金转化率IBRXKREF
| Q4 25 | — | — | ||
| Q3 25 | — | 1.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 6.54× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.19× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
